© 2024 Bennett Βιομηχανία Φαρμάκων. All rights reserved. Terms of Use – Privacy Policy
Developed with ❤ by ADS Solutions
Invest in Health, Create the Future
Bennet Investment Plan
Research & Development
Industrial Research of high Value Added Medicines (VAM) for the Respiratory System according to Quality by Design principles.
Research & Development
Industrial Research of high Value Added Medicines (VAM) for the Respiratory System according to Quality by Design principles.
The R&D Investment Plan of Bennett Pharmaceutical Company aims to R&D of high Value Added Medicines for Respiratory Diseases.
Πέρα από την ανάπτυξη κλασικών γενοσήμων φαρμάκων όπου το προϊόν αναφοράς δεν προστατεύεται από κάποιο δίπλωμα ευρεσιτεχνίας (off patent), η Βιομηχανία Φαρμάκων Bennett επενδύει σημαντικά στην E&A νέων φαρμάκων, οριακής καινοτομίας και συνεπακόλουθης υψηλής προστιθέμενης αξίας.
This category includes products which are different in terms of pharmaceutical form or/and content comparing to already approved medicines, covering thus specific patient needs (e.g. easier administration and flexible dosing schedule that lead to better treatment compliance).
Moreover, priority is given to the development of products for which there are no already approved generic products in the Greek market, as well as fixed dose drug combinations (FDCs), aiming to the dilatation of the doctor's prescription choices, but also to unmet medical needs coverage.
| Project Code: | ΤΑCL1-0480686 |
| Project budget: | 6.650.000,00 € |
| EU Funding: | 3.990.000,00 € |
The project was implemented under the action "The Reform of the clawback system and the Acceleration of investments in the Health Sector" of The Greek National Recovery and Resilience Plan: “Greece 2.0”, financed by European Union - NextGenerationEU.
Factory Facilities
Digital Growth
English 
Ελληνικά